Terumo gets ECA support for OrganOx acquisition. Manufacturing & equipment Asia-Pacific, Europe JBIC signed a JPY49 billion ($307.1 million) loan with Terumo to fund part of its acquisition of UK organ preservation device company OrganOx. The financing is being provided in co-financing with private financial institutions, bringing the total co-financing amount to JPY99 billion ($620.4... Exclusive subscriber content... Not yet a subscriber? Join TXF Limited today to continue accessing content without any restrictions Or to request access to TXF Intelligence contact TXF Limited

Terumo announces US launch of safety syringe. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. Terumo Medical has announced the launch of its SurTract Safety Syringe in the US, incorporating Roncadelle Operations' SafeR passive safety technology. The syringe will be distributed to clinics, emergency-care settings and hospitals across the country starting from the first quarter of this year. The SafeR technology equips the SurTract Safety Syringe with a fully passive, automatic retraction mechanism. This feature withdraws the needle into the plunger after use immediately, aiming to reduce needle-stick injury risks for healthcare professionals. The system also maintains standard clinical technique while enhancing safety and ease of use. The SurTract Safety Syringe also offers a needle selection that can be customised specifically for use with SurTract Syringes, enabling physicians to choose combinations best suited to patient needs. In addition, the syringe provides a blunt needle option, which helps prevent dullness and allows for needle replacement during aspiration. US tariffs are shifting - will you react or anticipate? Don't let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. The design contributes to less medical waste by eliminating an external plastic safety sheath. Terumo vice-president Bob Klock said: "The SurTract Syringe combines Terumo's trusted clinical know-how with Roncadelle's validated SafeR technology to deliver a simple, effective solution for safer injections. It gives healthcare providers more - and better - treatment options for their patients, which is our ultimate goal." Roncadelle operations chief business development officer Dr Fred Metzmann said: "Terumo has significantly advanced injection safety with the integration of our SafeR technology. Together, we are delivering a next-generation syringe system that is intuitive, reliable, and engineered to protect healthcare professionals." The company's SafeR product line includes needle-guard systems and passive safety syringes designed for safe injection and protection in clinical environments. In October 2025, Terumo completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.